MDMB-CHMICA

MDMB-CHMICA (also incorrectly known as MMB-CHMINACA) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of tert-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.

Pharmacology

MDMB-CHMICA acts as a highly potent full agonist of the CB1 receptor with an efficacy of 94% and an EC50 value of 0.14 nM, which is approximately 8 times lower than the EC50 of JWH-018 (1.13 nM) and twofold lower than that of AB-CHMINACA (0.27 nM).

Side effects

The side effects of MDMB-CHMICA are not well documented, but reports from users suggest that the effects are similar to those of other potent synthetic cannabinoids. These may include psychosis, seizures, agitation, tachycardia, and cardiac arrest.

Legal status

As of October 2015, MDMB-CHMICA is a controlled substance in China. It is also banned in Sweden, and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) issued a warning about the substance in 2014.

See also

• List of AM cannabinoids
• List of JWH cannabinoids
• 5F-AB-PINACA
• 5F-ADB
• 5F-AMB
• 5F-APINACA

MDMB-CHMICA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia